Paniz Zarand

Paniz Zarand


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PSPaniz Sabeghi
Paniz Sabeghi
PZPaniz Zarand
Paniz Zarand
SZSina Zargham
Sina Zargham
BGBatis Golestany
Batis Golestany
ASArya Shariat
Arya Shariat
AGAli Gholamrezanezhad
Ali Gholamrezanezhad
This study delineates the pivotal role of imaging within the field of neurology, emphasizing its significance in the diagnosis, prognostication, and evaluation of treatment responses for central nervous system (CNS) tumors. A comprehensive understanding of both the capabilities and limitations inherent in emerging imaging technologies is imperative for delivering a heightened level of personalized care to individuals with neuro-oncological conditions. Ongoing research in neuro-oncological imaging endeavors to rectify some limitations of radiological modalities, aiming to augment accuracy and efficacy in the management of brain tumors. This review is dedicated to the comparison and critical examination of the latest advancements in diverse imaging modalities employed in neuro-oncology. The objective is to investigate their respective impacts on diagnosis, cancer staging, prognosis, and post-treatment monitoring. By providing a comprehensive analysis of these modalities, this review aims to contribute to the collective knowledge in the field, fostering an informed approach to neuro-oncological care. In conclusion, the outlook for neuro-oncological imaging appears promising, and sustained exploration in this domain is anticipated to yield further breakthroughs, ultimately enhancing outcomes for individuals grappling with CNS tumors.

5 March 2025 in Health Science Reports
Verified
Journal Article
Open access
ASAryan Salahi‐Niri
Aryan Salahi‐Niri
PZPaniz Zarand
Paniz Zarand
NMNegar Mansouri
Negar Mansouri
PRParvaneh Rastgou
Parvaneh Rastgou
OYOmid Yazdani
Omid Yazdani
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
Background and Aims: Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Chemotherapy remains a primary therapeutic approach, but patient responses vary significantly, emphasizing the need for reliable biomarkers. This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies.Methods: We conducted a narrative review by searching Scopus, PubMed, and Google Scholar for studies focusing on Ki‐67, PCNA, Cyclin D1, and PHH3 in relation to pancreatic cancer and chemotherapy. The literature was reviewed to evaluate the role of these markers in predicting chemotherapy response, tumor progression, and overall patient survival.Results: The review highlights the clinical significance of these markers. Ki‐67 and PCNA are associated with cell proliferation, while Cyclin D1 regulates cell cycle progression and PHH3 is linked to mitotic activity. High expression levels of these markers often correlate with increased tumor aggressiveness and poorer patient outcomes. Moreover, they show promise in predicting chemotherapy response, which can inform tailored therapeutic strategies. However, challenges remain, including standardization of detection methods and determination of optimal cutoff values.Conclusion: Proliferative markers such as Ki‐67, PCNA, Cyclin D1, and PHH3 hold potential as predictive and prognostic tools in pancreatic cancer management. Their integration into clinical practice could improve the accuracy of treatment decisions and enhance patient outcomes. Further research and validation are necessary to overcome existing challenges and optimize their application in personalized oncology.

8 April 2025 in Health Science Reports
Verified
Journal Article
Open access
ASAryan Salahi‐Niri
Aryan Salahi‐Niri
PZPaniz Zarand
Paniz Zarand
FSFatemeh Shojaeian
Fatemeh Shojaeian
NMNegar Mansouri
Negar Mansouri
OYOmid Yazdani
Omid Yazdani
BJBehnaz Jahanbin
Behnaz Jahanbin
Background and Aims: Breast cancer is the most common cancer and a leading cause of cancer‐related death among women globally. Determining which patients will benefit from chemotherapy remains challenging. Proliferative markers such as Ki‐67, mini chromosome maintenance (MCM) proteins, and proliferating cell nuclear antigen (PCNA) offer valuable insights into tumor growth and treatment response. This review evaluates their clinical roles, with a focus on chemotherapy implications and emerging digital pathology techniques for marker quantification.Methods: A narrative review was conducted by searching PubMed, Scopus, and Google Scholar for studies related to Ki‐67, MCM, PCNA, breast cancer, and chemotherapy. Studies were thematically categorized into five areas. A bibliometric analysis of publications from 2000 to April 2023 was performed using the Bibliometrix R package and VOSviewer to assess research trends and thematic evolution.Results: Eighty studies were included in the narrative synthesis. Ki‐67 is the most commonly used marker, particularly useful in predicting response to neoadjuvant chemotherapy (NAC). MCM proteins show promise for identifying proliferative potential across tumor grades, while PCNA is associated with aggressive tumor features and poor prognosis. Post‐chemotherapy changes in Ki‐67 levels are linked to survival outcomes. Bibliometric analysis revealed a shift in research focus from basic mechanisms to clinical applications and digital quantification.Conclusion: Proliferative markers play an essential role in breast cancer management. Ki‐67 remains a key predictor of chemotherapy response, while MCM and PCNA offer complementary prognostic insights. Integration of these markers with digital pathology and AI‐driven tools may enhance diagnostic accuracy and personalized treatment strategies. Standardization of assessment methods is crucial for broader clinical application.

10 December 2024 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
DADorsa Alijanzadeh
Dorsa Alijanzadeh
SMShahrzad Moghim
Shahrzad Moghim
PZPaniz Zarand
Paniz Zarand
MAMohammad Ali Akbarzadeh
Mohammad Ali Akbarzadeh
YZYasaman Zarinfar
Yasaman Zarinfar
IKIsa Khaheshi
Isa Khaheshi

1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Acute myeloid leukemia (AML) remains defined by therapeutic resistance, adverse genetic heterogeneity, and poor long-term survival, underscoring the need for mechanistically informed regimens that exploit core stress-adaptation liabilities. Polo-like kinase 1 (PLK1) is a central regulator of replication recovery and mitotic progression, yet direct PLK1 inhibitors have been limited by tolerability and incomplete target suppression. Here, we define a clinically actionable strategy that functionally targets PLK1 by combining inhibition of the AAA+ ATPase p97/valosin-containing protein with the hypomethylating agent decitabine (DAC). Using AML cell lines, primary patient specimens, and an orthotopic in vivo model, we show that the clinically relevant p97 inhibitor CB-5339 induces proteotoxic and replication stress, activates the unfolded protein response, and triggers apoptosis. Formal synergy analyses demonstrate that CB-5339 and DAC cooperate across molecular subtypes, including FLT3-ITD+, KMT2A-rearranged, and TP53-mutant AML, to reduce cell viability at pharmacologically relevant concentrations. Transcriptomic, biochemical, and genetic studies identify synergistic suppression of PLK1 as a central consequence of combination treatment, converting stress-dependent PLK1 reliance into a therapeutic vulnerability. Consistent with this mechanism, PLK1 knockdown phenocopies the antileukemic effects of the combination and enhances sensitivity to both agents. In vivo, CB-5339/DAC is well tolerated, significantly prolongs survival, reduces leukemic burden, and suppresses PLK1 in bone marrow blasts. Together, these data establish p97 inhibition as a rational means to exploit replication and proteotoxic stress in AML and provide strong rationale for clinical evaluation of CB-5339 plus DAC in high-risk disease. Significance: This study defines a clinically actionable strategy to overcome therapeutic resistance in AML by functionally suppressing PLK1 through combined p97 inhibition and hypomethylating therapy. By exploiting convergent proteotoxic and replication stress, the regimen produces robust, well-tolerated antileukemic activity across high-risk genetic subtypes, supporting near-term clinical evaluation.

26 June 2026
Verified
Other
Open access
Steffan T. NawrockiSteffan T. Nawrocki
Steffan T. Nawrocki
NWNing Wang
Ning Wang
CEClaudia M. Espitia
Claudia M. Espitia
HWHarley Wu
Harley Wu
CCClaudia S Villa Celi
Claudia S Villa Celi
KKKevin Kelly
Kevin Kelly
Figure S4. Gene modulation overlap between MOLM-13 and MV4-11 cells.